| Description | (Rac)-Byakangelicin (7H-Furo[3,2-g][1]benzopyran-7-one, 9-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-) is an antineoplastic agent. |
| Synonyms | 白当归素, Bjacangelicin, Bjakangelicin, Biacangelicin, 7H-Furo[3,2-g][1]benzopyran-7-one, 9-(2,3-dihydroxy-3-methylbutoxy)-4-methoxy-, Byakangelicin |
| molecular weight | 334.32 |
| Molecular formula | C17H18O7 |
| CAS | 19573-01-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 25 mg/mL (74.78 mM) |
| References | 1. Yang J, et al. Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes. Br J Pharmacol. 2011 Jan;162(2):441-51. 2. Shin KH, et al. Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats. Phytomedicine. 1998 Apr;5(2):121-7. |